Walder Wyss advised 65 Equity Partners in the partial acquisition of HAS Healthcare Advanced Synthesis SA
31 marzo 2025
Walder Wyss advised 65 Equity Partners in the acquisition of approximately 40% of the shares in HAS Healthcare Advanced Synthesis SA. At the same time, HAS Healthcare Advances Synthesis SA is acquiring Cerbios-Pharma SA to create a leading international group in the CDMO sector.
This major acquisition in Ticino, Switzerland will allow the two companies to combine their production capacities, chemical and biological expertise, know-how and technological capabilities. The move creates new opportunities for growth and drives business development to establish itself as a leading international quality provider in the CDMO (Contract Development and Manufacturing Organization) industry. 65 Equity Partners focuses on partnering with family-owned and entrepreneur-led businesses to drive long-term growth and innovation through similar M&A processes.
Walder Wyss advised 65 Equity Partners as Swiss legal advisor on the transaction. The team was led by Davide Jermini (Partner, Corporate/M&A) and Martina Madonna-Quadri (Senior Associate, Corporate/M&A). It included Andreas Wildi (Partner, Healthcare and Life Sciences), Stefano Codoni (Partner, Intellectual Property), Fabienne Limacher (Partner, Tax), Marco Galli (Counsel, Corporate/M&A), Alex Domeniconi (Managing Associate, Employment) and Celine Weber (Managing Associate, Healthcare & Life Sciences).